Lexeo Therapeutics, Inc. (LXEO) Stock Price & Analysis
Lexeo Therapeutics, Inc. (LXEO) is trading at USD 3.03, up 6.13% today, as of November 18, 2026 at 20:53 UTC (US market open; quotes may be delayed), according to Nexqual market data.
LXEO last closed at USD 2.86; today's session has ranged USD 2.76–3.09 on volume of 1,517,470 shares. Market capitalization is $250.85M, with a 52-week range of USD 2.55–10.99 (NGM). Source: Nexqual, retrieved November 18, 2026 at 20:53 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LXEO.md
Key facts (LXEO)
- Insider open-market sales, last ~7 months: 9 Form 4 filings, $323K; 9 not under a Rule 10b5-1 plan ($323K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.78 on a 1–5 scale) (9 analysts), mean target USD 25.11 (range 9–42).
- Total return with dividends: 1Y -67.0% vs S&P 500 +11.9%; 5Y -69.8% vs S&P 500 +66.7%.
- Latest earnings report: 2026-11-16 (next date not yet announced).
- Dividend: LXEO paid no cash dividend in the last five years.
- Short interest: 23.98% of float (as of 2026-10-30), 10.5 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LXEO)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $654K | — | — | — | — |
| Operating income | -$60.5M | -$68.5M | -$106M | -$109M | -$114M |
| Net income | -$59.3M | -$66.4M | -$98.3M | -$100.0M | -$105M |
| EPS (diluted) | -$36.36 | -$12.40 | -$3.09 | -$1.86 | — |
| Free cash flow | -$55.2M | -$59.6M | -$81.6M | -$99.0M | -$87.7M |
| Operating margin | -9252.1% | — | — | — | — |
| Net margin | -9063.8% | — | — | — | — |
| Cash + short-term investments | $77.3M | $121M | $129M | $182M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (LXEO)
P/B 1.2x · FCF yield -34.97% · Earnings yield -41.97%
Insider sales (SEC Form 4, open-market, last ~7 months) (LXEO)
0 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Tamayo Louis Edward | Chief Financial Officer | 4,117 | $20K | 4.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18 | Townsend Richard Nolan | Chief Executive Officer | 3,345 | $17K | 0.9% | No | Too little history (no open-market trades in 2023) |
| 2026-08-18 | Otero Jose Manuel | Chief Operating Officer | 1,304 | $6K | 0.9% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-01 | Tamayo Louis Edward | Chief Financial Officer | 4,641 | $21K | 4.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Otero Jose Manuel | Chief Operating Officer | 4,666 | $21K | 3.3% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-01 | Bhalla Narinder Pal | Chief Medical Officer | 22,306 | $99K | 21.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Townsend Richard Nolan | Chief Executive Officer | 25,947 | $116K | 6.4% | No | Too little history (no open-market trades in 2023) |
| 2026-05-18 | Otero Jose Manuel | Chief Operating Officer | 1,302 | $7K | 1% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-18 | Townsend Richard Nolan | Chief Executive Officer | 3,342 | $17K | 1% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (LXEO)
Consensus Buy (mean 1.78 on a 1–5 scale), 9 analysts; mean target USD 25.11 (low 9, high 42).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-12 | Cantor Fitzgerald | Reiterated | Overweight | $23 |
| 2026-09-23 | Leerink Partners | Maintained | Outperform | $15 |
Total return (dividends reinvested) (LXEO)
| 1Y (from 2025-11-18) | 5Y (from 2023-10-30) | |
|---|---|---|
| Total return | -67.0% | -69.8% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | -67.0% | -32.5% |
| Volatility (annualized) | 73.9% | 102.5% |
| Max drawdown | -75.3% (Dec 2025→Oct 2026) | -88.8% (Jul 2024→Apr 2025) |
Dividends (LXEO)
LXEO paid no cash dividend in the last five years.
Short interest (LXEO)
17,037,063 shares sold short, 23.98% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 19,246,976 shares (-11.5%). Days to cover: 10.5 (short shares ÷ average daily volume).
LXEO earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Nov 16, 2026 | Quarter ended Sep 30, 2026 | −$0.43 | −$0.32 | Miss −34.4% | -0.5% |
| Aug 12, 2026 | Quarter ended Jun 30, 2026 | −$0.30 | −$0.28 | Miss −7.1% | +3.8% |
| May 11, 2026 | Quarter ended Mar 31, 2026 | −$0.25 | −$0.30 | Beat +16.7% | -2.2% |
| Mar 30, 2026 | Quarter ended Dec 31, 2025 | −$0.27 | −$0.30 | Beat +10.0% | +5.1% |
| Nov 5, 2025 | — | — | — | — | +0.8% |
| Oct 17, 2025 | — | — | — | — | +5.1% |
| Aug 14, 2025 | — | — | — | — | +0.0% |
| May 12, 2025 | — | — | — | — | +5.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
LXEO recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | Schedule 13G/A | OrbiMed Advisors LLC, OrbiMed Capital LLC: 3.9% of shares, passive 5%+ holder (amended) |
| Nov 16, 2026 | Schedule 13G/A | Vestal Point Capital, LP, Ryan Wilder: 6.3% of shares, passive 5%+ holder (amended) |
| Nov 16, 2026 | Schedule 13G/A | Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC: 0.0% of shares, passive 5%+ holder (amended) |
| Nov 16, 2026 | Schedule 13G/A | JANUS HENDERSON GROUP Ltd.: 7.2% of shares, passive 5%+ holder (amended) |
| Nov 16, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Nov 16, 2026 | 8-K | Quarterly results; Regulation FD disclosure; Other material event “In the press release described in Item 2.02 above, the Company announced positive interim Phase I/II clinical data and regulatory updates for LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (" PKP2-ACM "). As part of the press release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on November 16, 2026 to discuss the interim Phase I/II clinical data of LX2020 for the treatment of PKP2-ACM. Also on November 16, 2026, the Company posted on its…” |
| Nov 16, 2026 | Schedule 13G/A | BALYASNY ASSET MANAGEMENT L.P., BAM GP LLC: 10.0% of shares, passive 5%+ holder (amended) |
| Nov 13, 2026 | Schedule 13G/A | Affinity Asset Advisors, LLC, Michael Cho: 9.8% of shares, passive 5%+ holder (amended) |
| Nov 10, 2026 | Schedule 13G | STATE STREET CORPORATION: 4.4% of shares, passive 5%+ holder |
| Oct 13, 2026 | Schedule 13G | passive 5%+ holder |
| Sep 29, 2026 | 8-K | Completed an acquisition or sale of assets; Unregistered sale of shares |
| Sep 22, 2026 | 8-K | Entered a material agreement; Other material event |
| Aug 14, 2026 | Schedule 13G | passive 5%+ holder |
| Aug 14, 2026 | Schedule 13G/A | passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
LXEO suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Solid Biosciences Inc. (SLDB) | “With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…” |
| Partner | Voyager Therapeutics, Inc. (VYGR) | “With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…” |
| Partner | NEUROCRINE BIOSCIENCES INC (NBIX) | “With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…” |
| Partner | Larimar Therapeutics, Inc. (LRMR) | “With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…” |
| Partner | PTC THERAPEUTICS, INC. (PTCT) | “With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…” |
| Partner | Cornell University and Adverum Biotechnologies | “In January 2021, we entered into a license agreement with Adverum, which we amended in February 2022 pursuant to the First Amendment to the Adverum Agreement, such agreement as amended, the Amended Adverum Agreement.” |
| Partner | Stelios Therapeutics | “The net decrease of $10.3 million in total research and development expenses for the year ended December 31, 2025 compared to the year ended December 31, 2024 was primarily due to decreases in (i) milestone expenses of $6.1 million, consisting primarily of a $6.0 million development milestone for our LX2020 program that was achieved during the third quarter of 2024 and subsequently paid to the selling shareholders…” |
| Partner | Johnson & Johnson (JNJ) | “Abiomed, Inc. (Johnson & Johnson subsidiary)—In December 2025, the Company entered into a Collaboration Agreement with Abiomed, Inc. ("Abiomed" and the "Abiomed Agreement"), to investigate localized cardiac delivery of gene therapy.” |
Quoted from the company's 10-K filed Mar 30, 2026.
LXEO company outlook (results filed Nov 16, 2026)
- “Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020 Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK – November 16, 2026 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc.”
Quoted word-for-word from the SEC 8-K results press release.
LXEO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $-0.35 | $-0.33 | −$0.02 | $0 | 7 |
| Next quarter (ends Mar 2027) | $-0.36 | $-0.34 | −$0.02 | $0 | 4 |
| Current fiscal year (ends Dec 2026) | $-1.34 | $-1.20 | −$0.14 | $0 | 6 |
| Next fiscal year (ends Dec 2027) | $-1.44 | $-1.38 | −$0.06 | $0 | 8 |
LXEO options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 2 | 314.0% | ±99.5% |
| Dec 18, 2026 | 30 | 68.8% | ±19.4% |
| Feb 19, 2027 | 93 | 74.3% | ±123.8% |
| May 21, 2027 | 184 | 388.0% | ±37.3% |
30-day implied volatility 101.5% vs 95.3% realized over the last 30 trading days. Put/call ratio (volume) 0.59. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 18, 2026 at 20:53 UTC)
| Price | USD 3.03 |
|---|---|
| Change | ▲ 6.13% (up) |
| Previous Close | USD 2.86 |
| Open | USD 2.81 |
| Day Range | USD 2.76 – 3.09 |
| 52-Week Range | USD 2.55 – 10.99 |
| Volume | 1,517,470 shares |
| Market Cap | $250.85M |
| Exchange | NGM |
Technical Analysis (LXEO)
Nexqual's technical model rates LXEO "SELL" based on 1 bullish and 4 bearish signals across 129 daily candles, as of November 18, 2026 at 20:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.59 (neutral) |
| vs SMA50 | Below (USD 3.28) |
| MACD | -0.07 (negative) |
Analyst Ratings (LXEO)
Wall Street analysts rate LXEO "Buy" based on 9 analysts, with a mean price target of USD 25.11 (range USD 9–42), per Nexqual as of November 18, 2026 at 20:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 25.11 |
| High Target | USD 42 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (LXEO)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD -0.35 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -0.43 vs est -0.32 ▼ miss |
| 2026-06-30 | USD -0.3 vs est -0.28 ▼ miss |
| 2026-03-31 | USD -0.25 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.3 ▲ beat |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Financials & Fundamentals (LXEO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -62.39% |
| Debt / Equity | 0.03 |
| Current Ratio | 8.69 |
| Total Cash | $194.78M |
| Total Debt | $6.25M |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Financial Health Score (LXEO)
Nexqual rates Lexeo Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $195M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$99M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -49%, ROA -43.2% (last 4 quarters, SEC) |
Ownership (LXEO)
| Insider Ownership | +0.63% |
|---|---|
| Institutional Ownership | +117.44% |
| Shares Outstanding | 82.79M |
| Float | 50.23M |
| Short % of Float | +23.98% |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Leadership (LXEO)
Lexeo Therapeutics, Inc. is led by R. Nolan Townsend, CEO & Director, per Nexqual as of November 18, 2026 at 20:53 UTC.
| CEO & Director | R. Nolan Townsend |
|---|---|
| CFO & Principal Accounting Officer | Louis Tamayo |
| Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | Ronald G. Crystal |
| Chief Operating Officer | Jose Manuel Otero |
| Senior Vice President of Regulatory Affairs | Keith Wonnacott |
Major Backers & Investors (LXEO)
Notable institutional backers of Lexeo Therapeutics, Inc. include Affinity Asset Advisors, Llc, Montanova Capital LLC, RA Capital Management, L.P., according to Nexqual as of November 18, 2026 at 20:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Affinity Asset Advisors, Llc | 8.75% |
| Montanova Capital LLC | 7.71% |
| RA Capital Management, L.P. | 6.04% |
| Frazier Life Sciences Management, L.P. | 5.83% |
| JPMorgan | 5.54% |
| Vestal Point Capital, LP | 5.22% |
| Citadel | 5.12% |
| Balyasny Asset Management LP | 4.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.22% |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
From Lexeo Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe our proprietary Sf9 baculovirus process will allow us to produce vectors at the necessary scale to support the patient populations we are targeting at a cost-of-goods profile similar to what the pharmaceutical marketplace has seen with biologics.
- In October 2025, in response to our questions regarding the possibility of a faster path to a Biologics License Application, or BLA, the FDA indicated openness to a BLA submission for accelerated approval that includes clinical data from the ongoing Phase 1/2 studies of LX2006 pooled with new clinical data to be generated in the planned pivotal study.
- We actively seek to protect our proprietary technology, inventions, and other intellectual property that is commercially important to the development of our business by a variety of means, such as seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties.
- We also may rely on trade secrets and know-how relating to our proprietary technology platform, on continuing technological innovation and on in-licensing opportunities to develop, strengthen and maintain the strength of our position in the field of gene therapy that may be important for the development of our business.
Partnerships
- In April 2024 we announced a license agreement with Cornell University for intellectual property rights including current and future clinical data from the ongoing Weill Cornell Medicine investigator-initiated trial of LX2006.
- Under the Cornell First License Agreement, we are obligated to pay Cornell University up to $8.4 million for each portfolio upon the achievement of specific clinical and regulatory milestones.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries.
- The FDA's policies, and the policies of foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.
- We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.
- Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 97.7 | ▲ 0.93% |
| BLTE | Belite Bio, Inc | USD 156.45 | ▼ 0.81% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.68 | ▼ 0.67% |
| IBRX | ImmunityBio, Inc. | USD 6.71 | ▲ 7.11% |
| IMVT | Immunovant, Inc. | USD 33.24 | ▲ 0.09% |
| CGON | CG Oncology, Inc. | USD 79.85 | ▲ 1.15% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt